Cognigen Networks, Inc. v. Cognigen Corp.

174 F. Supp. 2d 1134, 2001 U.S. Dist. LEXIS 21799, 2001 WL 1563366
CourtDistrict Court, W.D. Washington
DecidedDecember 3, 2001
DocketC01-1077L
StatusPublished
Cited by3 cases

This text of 174 F. Supp. 2d 1134 (Cognigen Networks, Inc. v. Cognigen Corp.) is published on Counsel Stack Legal Research, covering District Court, W.D. Washington primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Cognigen Networks, Inc. v. Cognigen Corp., 174 F. Supp. 2d 1134, 2001 U.S. Dist. LEXIS 21799, 2001 WL 1563366 (W.D. Wash. 2001).

Opinion

ORDER DISMISSING ACTION FOR LACK OF PERSONAL JURISDICTION

LASNIK, District Judge.

This matter comes before the Court on defendants Cognigen Corp. (“Cognigen-NY”) and Dr. Thaddeus Grasela’s (“Dr.Grasela”) motion to dismiss plaintiffs complaint on the ground that the Court lacks personal jurisdiction over the defendants. Alternatively, defendants ask the Court to transfer the venue to the Western District of New York. For the reasons discussed below, defendants’ motion to dismiss for lack of personal jurisdiction is granted.

I. BACKGROUND

Plaintiff Cognigen Networks (“Cogni-gen-WA”) is a publicly-traded Colorado corporation. Seattle is its principal place of business. It is a marketer of telecommunications and technology products such as long distance services, calling cards and computers. It operates through a network of 135,000 independent agents who earn commissions on sales.

Defendant Cognigen-NY is a New York corporation with Williamsville, New York, as its principal place of business. Dr. Grasela is its founder and president. Cog-nigen-NY, known as Pharmaceutical Outcomes Research, Inc. (“PHOR”) before September 2000, designs pharmacological tests and clinical research studies, and analyzes clinical test data. Its clients are companies in the health care and pharmaceutical industries. Its web site (http://www.cognigencorp.com) describes its services, invites prospective employment candidates to apply, announces upcoming conferences and serves as an archive for an e-mail mailing list on the topic of data analysis. While most of Cognigen-NY’s work is done at its headquarters, its *1136 employees sometimes travel to clients’ offices and attend conferences elsewhere. Cognigen has no branch offices, employees or representatives in the state of Washington. Dr. Grasela has visited the state three times in the last 10 years, twice for a conference and once at a client’s request.

Cognigen-NY and Cognigen-WA eo-ex-isted peacefully until 2000 when their claims to the Cognigen name collided. In May 1999, PHOR filed an application with the U.S. Patent and Trademark Office (“USPTO”) seeking federal registration for the service mark “Cognigen” in connection with business consulting for pharmaceutical and healthcare firms, electronic data storage and some forms of pharmaceutical research. In January 2000, Cognigen-WA filed the “Cognigen” mark for registration with the USPTO for use in telecommunications services. 1 Cognigen-WA became aware of a potential conflict in April 2000 as a result of a USPTO records search. The president and CEO of Cognigen-WA, Darrell Hughes, contacted Dr. Grasela in June 2000 to determine the nature of goods and services that Cognigen-NY offered. Apparently as a result of the exchange that followed and based on independent research, Mr. Hughes did not file an opposition to Cognigen-NY’s application. (Hughes Decl. of 10/15/2001 at ¶¶ 6-7.) Mr. Hughes claims that he was not informed of PHOR’s imminent plans to change the company name to Cognigen. Thereafter, Cognigen-WA began receiving e-mail at its cognigen.com e-mail address that was intended for Cognigen-NY, and it became aware of the corporate name change as well as of Cognigen-NY’s web site at the address http://www.cognigen-corp.com. In December 2000, Cognigen-WA’s attorney wrote to Cognigen-NY’s lawyer objecting to the allegedly expanded use of the Cognigen mark and assertions on Cognigen-NY’s web site that described Cognigen-NY as pushing the “limits of information technology and communications to create new options ...” and as a “global analytical communications tool.” Cognigen-NY’s attorney wrote back denying that the company had expanded into new areas and that its services were “limited to the pharmaceutical and healthcare industries and relate to statistical analyses and outcome research studies.” (Grasela Exhibit B, Ellen Simpson Letter of 1/26/2001, at 2.) The letter further stated that when the descriptions of Cognigen-NY were read in the context of the surrounding paragraphs, it was clear that the company did data analysis used to market pharmaceutical products. The letter concluded that since the companies operated in separate spheres “we are of the opinion that the two marks can probably co-exist in the marketplace.” Id. Cognigen-NY received no communication from Cogni-gen-WA for about six months.

The clash of the Cognigens accelerated in the summer of 2001. In July, a client of Cognigen-NY mistakenly sent an e-mail to Cognigen-WA with an invitation to a conference in Brazil. In a reply e-mail, an employee of Cognigen-WA lightheartedly informed the sender of the mistake and then went on to complain that Cognigen-NY’s logo had been designed to look like Cognigen-WA’s, that Cognigen-WA was forwarding several e-mails per day to Cog-nigen-NY, and that Cognigen-NY was infringing on Cognigen-WA’s intellectual property. When officials at Cognigen-NY heard about this, they were not amused. The company’s attorney sent an angry letter threatening to sue for libel by July 13, 2001 unless the Cognigen-WA employee apologized to the sender. Additionally, Cognigen-NY demanded that Cognigen-WA forward any misdirected e-mail and *1137 refrain from replying to e-mail intended for Cognigen-NY.

On July 13, 2001, Cognigen-WA filed a complaint in the Western District of Washington claiming that Cognigen-NY had infringed its trademark and engaged in unfair competition in violation of state and federal laws. It sought damages, attorney’s fees and costs, a declaration that it had not libeled defendants and an injunction preventing defendants from further use of the Cognigen mark.

In response, Cognigen-NY and Dr. Grasela have challenged this Court’s exercise of personal jurisdiction. They claim that Cognigen-WA cannot show that either general or specific jurisdiction exists here. Even if the Court were to find that jurisdiction is properly asserted, they ask the Court to transfer this action to the Western District of New York, which, they claim, is a more convenient and suitable venue. Cognigen-WA counters that jurisdiction is properly asserted under recent Ninth Circuit case law.

II. DISCUSSION

On defendant’s motion to dismiss for lack of personal jurisdiction, it is the plaintiffs burden to show that jurisdiction is proper. See Lee v. City of Los Angeles, 250 F.3d 668, 692 (9th Cir.2001). At this preliminary stage, plaintiff need only make “a prima facie showing of jurisdiction.” Ziegler v. Indian River County, 64 F.3d 470, 473 (9th Cir.1995). Plaintiff must allege facts to support its case; these are assumed to be true for jurisdictional analysis. See, e.g, Omeluk v. Langsten Slip & Batbyggeri A/S, 52 F.3d 267, 268 (9th Cir.1995). The exercise of jurisdiction has to satisfy the requirements of the state long-arm statute and Constitutional due process. See id. at 269.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

U.S. Vestor, LLC v. Biodata Information Technology AG
290 F. Supp. 2d 1057 (N.D. California, 2003)
Pavlovich v. Superior Court
58 P.3d 2 (California Supreme Court, 2002)

Cite This Page — Counsel Stack

Bluebook (online)
174 F. Supp. 2d 1134, 2001 U.S. Dist. LEXIS 21799, 2001 WL 1563366, Counsel Stack Legal Research, https://law.counselstack.com/opinion/cognigen-networks-inc-v-cognigen-corp-wawd-2001.